Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also reported positive Phase 1 data for RAD301 in pancreatic cancer and advanced dosing in trials for RAD202, RAD204, and RV-01 targeting various solid tumors. Financially, Radiopharm strengthened its position through a $12.5 million institutional placement and a $3 million share purchase plan, with $7.5 million cash on hand at quarter-end. Upcoming milestones include further clinical trial advancements and regulatory steps to develop precision cancer therapies.
Radiopharm Theranostics business update provides context for health sector trends. For readers following the health sector, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health stocks, 82 rose and 47 fell. Notable movers include ALMS at USD 7.04 with a 1-day change of +4.45%, HRTX at USD 0.29 with +4.43%, and MMED at USD 17.74 with -2.95%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
